These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35258578)

  • 1. Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer.
    Fakih M; Sandhu J; Wang C; Kim J; Chen YJ; Lai L; Melstrom K; Kaiser A
    JAMA Netw Open; 2022 Mar; 5(3):e221093. PubMed ID: 35258578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer.
    Symonds EL; Pedersen SK; Murray D; Byrne SE; Roy A; Karapetis C; Hollington P; Rabbitt P; Jones FS; LaPointe L; Segelov E; Young GP
    Cancer; 2020 Apr; 126(7):1460-1469. PubMed ID: 31909823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer.
    Snyder RA; Hu CY; Cuddy A; Francescatti AB; Schumacher JR; Van Loon K; You YN; Kozower BD; Greenberg CC; Schrag D; Venook A; McKellar D; Winchester DP; Chang GJ;
    JAMA; 2018 May; 319(20):2104-2115. PubMed ID: 29800181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations.
    Wong R; Tie J; Lee M; Cohen J; Wang Y; Li L; Ma S; Christie M; Kosmider S; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Int J Cancer; 2019 Jul; 145(2):540-547. PubMed ID: 30628066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation.
    Mo S; Ye L; Wang D; Han L; Zhou S; Wang H; Dai W; Wang Y; Luo W; Wang R; Xu Y; Cai S; Liu R; Wang Z; Cai G
    JAMA Oncol; 2023 Jun; 9(6):770-778. PubMed ID: 37079312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
    Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
    Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Ooki A; Shimozaki K; Kamiimabeppu D; Nakayama I; Wakatsuki T; Ogura M; Takahari D; Chin K; Yamaguchi K
    Cancer Med; 2021 Dec; 10(24):8820-8828. PubMed ID: 34821068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Circulating Tumor DNA for Methylated
    Musher BL; Melson JE; Amato G; Chan D; Hill M; Khan I; Kochuparambil ST; Lyons SE; Orsini J; Pedersen SK; Robb B; Saltzman J; Silinsky J; Gaur S; Tuck MK; LaPointe LC; Young GP
    Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2702-2709. PubMed ID: 32958500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer.
    Bansal VV; Belmont E; Godley F; Dhiman A; Witmer HD; Li S; Liao A; Eng OS; Turaga KK; Shergill A
    J Am Coll Surg; 2024 Jun; 238(6):1013-1020. PubMed ID: 38299640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen: Comparison of Surveillance Strategies Among Patients Who Underwent Resection of Colorectal Cancer-A Systematic Review and Meta-analysis.
    Dawood ZS; Alaimo L; Lima HA; Moazzam Z; Shaikh C; Ahmed AS; Munir MM; Endo Y; Pawlik TM
    Ann Surg Oncol; 2023 Jan; 30(1):259-274. PubMed ID: 36219278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial.
    Primrose JN; Perera R; Gray A; Rose P; Fuller A; Corkhill A; George S; Mant D;
    JAMA; 2014 Jan; 311(3):263-70. PubMed ID: 24430319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical validity of tissue carcinoembryonic antigen expression as ancillary to serum carcinoembryonic antigen concentration in patients curatively resected for colorectal cancer.
    Park JW; Chang HJ; Kim BC; Yeo HY; Kim DY
    Colorectal Dis; 2013 Sep; 15(9):e503-11. PubMed ID: 23711333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL
    Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer.
    Wang Y; Li L; Cohen JD; Kinde I; Ptak J; Popoli M; Schaefer J; Silliman N; Dobbyn L; Tie J; Gibbs P; Tomasetti C; Kinzler KW; Papadopoulos N; Vogelstein B; Olsson L
    JAMA Oncol; 2019 Aug; 5(8):1118-1123. PubMed ID: 31070668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
    Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
    World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
    Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoembryonic antigen directed PET-CECT scanning for postoperative surveillance of colorectal cancer.
    Vallam KC; Guruchannabasavaiah B; Agrawal A; Rangarajan V; Ostwal V; Engineer R; Saklani A
    Colorectal Dis; 2017 Oct; 19(10):907-911. PubMed ID: 28444968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of postoperative CEA for surveillance of recurrence after resection of primary colorectal cancer.
    Bhatti I; Patel M; Dennison AR; Thomas MW; Garcea G
    Int J Surg; 2015 Apr; 16(Pt A):123-128. PubMed ID: 25771102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA dynamics and response to immunotherapy in colorectal cancer.
    Gong J; Aguirre F; Hazelett D; Alvarez R; Zhou L; Hendifar A; Osipov A; Zaghiyan K; Cho M; Gangi A; Hitchins M
    Mol Clin Oncol; 2022 May; 16(5):100. PubMed ID: 35463213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer.
    Young GP; Pedersen SK; Mansfield S; Murray DH; Baker RT; Rabbitt P; Byrne S; Bambacas L; Hollington P; Symonds EL
    Cancer Med; 2016 Oct; 5(10):2763-2772. PubMed ID: 27726312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.